Drugs & Aging

, Volume 30, Issue 7, pp 503–512

Therapeutic Management of Primary Immunodeficiency in Older Patients

  • Nisha Verma
  • Anthony Thaventhiran
  • Benjamin Gathmann
  • for the ESID Registry Working Party
  • James Thaventhiran
  • Bodo Grimbacher
Review Article

DOI: 10.1007/s40266-013-0079-7

Cite this article as:
Verma, N., Thaventhiran, A., Gathmann, B. et al. Drugs Aging (2013) 30: 503. doi:10.1007/s40266-013-0079-7

Abstract

Primary immunodeficiency disease (PID) has traditionally been viewed as a group of illnesses seen in the paediatric age group. New advances in diagnosis and treatment have led to an increase in the number of elderly PID patients. However, there is lack of research evidence on which to base clinical management in this group of patients. Management decisions often have to be based therefore on extrapolations from other patient cohorts or from younger patients. Data from the European Society for Immunodeficiencies demonstrates that the vast majority of elderly patients suffer from predominantly antibody deficiency syndromes. We review the management of PID disease in the elderly, with a focus on antibody deficiency disease.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Nisha Verma
    • 1
  • Anthony Thaventhiran
    • 1
  • Benjamin Gathmann
    • 2
  • for the ESID Registry Working Party
  • James Thaventhiran
    • 1
  • Bodo Grimbacher
    • 1
    • 2
  1. 1.Department of Immunology and Molecular PathologyRoyal Free Hospital and University College LondonLondonUK
  2. 2.Centre of Chronic Immunodeficiency (CCI)University Medical Center Freiburg and University of FreiburgFreiburgGermany